Dean Schorno - Adaptive Biotechnologies CFO
ADPT Stock | USD 2.34 0.10 4.10% |
CFO
Mr. Dean L. Schorno is a Chief Financial Officer of the Company. Mr. Schorno oversees Adaptives financial infrastructure, investor relations and facilities management. Prior to Adaptive, he enjoyed 13 years in distinguished global leadership positions in financial, laboratory and business operations for Genomic Health
Age | 54 |
Address | 1165 Eastlake Avenue East, Seattle, WA, United States, 98109 |
Phone | 206 659 0067 |
Web | https://www.adaptivebiotech.com |
Adaptive Biotechnologies Management Efficiency
The company has return on total asset (ROA) of (0.166) % which means that it has lost $0.166 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5834) %, meaning that it created substantial loss on money invested by shareholders. Adaptive Biotechnologies' management efficiency ratios could be used to measure how well Adaptive Biotechnologies manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.44 in 2024. Return On Capital Employed is likely to drop to -0.37 in 2024. At this time, Adaptive Biotechnologies' Liabilities And Stockholders Equity is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 276.3 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 84.7 M in 2024.Similar Executives
Found 4 records | CFO Age | ||
Stephen DiPalma | Foghorn TherapeuticsInc | 65 | |
Adam Levy | Mineralys Therapeutics Common | 46 | |
Peter Lee | Cullinan Oncology LLC | 59 | |
Lucy CPA | AN2 Therapeutics | 65 |
Management Performance
Return On Equity | -0.58 | ||||
Return On Asset | -0.17 |
Adaptive Biotechnologies Leadership Team
Elected by the shareholders, the Adaptive Biotechnologies' board of directors comprises two types of representatives: Adaptive Biotechnologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Adaptive. The board's role is to monitor Adaptive Biotechnologies' management team and ensure that shareholders' interests are well served. Adaptive Biotechnologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Adaptive Biotechnologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
Yi Zhou, Chief Officer | ||
Ronald Taylor, Independent Director | ||
Ricardo Martinez, Chief Medical Officer | ||
Dean Schorno, CFO | ||
Nancy Hill, Senior Vice President General Manager - Research Products | ||
Daniel Rosenberg, Director | ||
Stacy Taylor, General VP | ||
Stephen Mengert, Director | ||
Gregory Scott, Independent Director | ||
Mark Adams, Chief Officer | ||
Julie Rubinstein, President COO | ||
Francis Lo, Chief Officer | ||
Sharon Benzeno, Chief Medicine | ||
Andrew Jordan, Chief Marketing Officer | ||
Chad MBA, CEO CoFounder | ||
Nitin Sood, Chief MRD | ||
Graham Cherrington, Pres and COO | ||
Thomas Hall, Chairman and CEO | ||
Jeffery Vender, Independent Director | ||
Steven Napolitano, Independent Director | ||
Tycho Peterson, Chief Officer | ||
Harlan Robins, Co-Founder, Chief Scientific Officer | ||
Kyle Piskel, Principal Officer | ||
James Muzzarelli, Executive Medical Director | ||
Frank Williams, CFO, Executive Vice President | ||
Susan Bobulsky, Chief MRD | ||
Richard Covert, Chairman of the Board | ||
Chad Robins, President CEO, Co-Founder | ||
Willis, Senior Vice President General Manager - Diagnostic Products | ||
Karina Calzadilla, Vice Relations | ||
Timothy Fielding, CFO and Treasurer | ||
MBA MBA, CEO CoFounder | ||
Traci Bowen, Sr. VP of HR | ||
Christopher Carlson, Founder |
Adaptive Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Adaptive Biotechnologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.58 | ||||
Return On Asset | -0.17 | ||||
Profit Margin | (1.32) % | ||||
Operating Margin | (1.00) % | ||||
Current Valuation | 236.94 M | ||||
Shares Outstanding | 145.09 M | ||||
Shares Owned By Insiders | 2.80 % | ||||
Shares Owned By Institutions | 97.61 % | ||||
Number Of Shares Shorted | 9.1 M | ||||
Price To Earning | 0.25 X |
Adaptive Biotechnologies Investors Sentiment
The influence of Adaptive Biotechnologies' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Adaptive. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Adaptive Biotechnologies' public news can be used to forecast risks associated with an investment in Adaptive. The trend in average sentiment can be used to explain how an investor holding Adaptive can time the market purely based on public headlines and social activities around Adaptive Biotechnologies Corp. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Adaptive Biotechnologies' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Adaptive Biotechnologies' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Adaptive Biotechnologies' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Adaptive Biotechnologies.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Adaptive Biotechnologies in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Adaptive Biotechnologies' short interest history, or implied volatility extrapolated from Adaptive Biotechnologies options trading.
Pair Trading with Adaptive Biotechnologies
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Adaptive Biotechnologies position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Adaptive Biotechnologies will appreciate offsetting losses from the drop in the long position's value.Moving together with Adaptive Stock
0.77 | KA | Kineta Inc Financial Report 9th of May 2024 | PairCorr |
0.76 | ME | 23Andme Holding | PairCorr |
Moving against Adaptive Stock
0.87 | YS | YS Biopharma Report 22nd of April 2024 | PairCorr |
0.72 | DOMH | Dominari Holdings | PairCorr |
0.58 | VCEL | Vericel Corp Ord Downward Rally | PairCorr |
0.57 | A | Agilent Technologies Financial Report 28th of May 2024 | PairCorr |
0.52 | DNTH | Dianthus Therapeutics Symbol Change | PairCorr |
The ability to find closely correlated positions to Adaptive Biotechnologies could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Adaptive Biotechnologies when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Adaptive Biotechnologies - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Adaptive Biotechnologies Corp to buy it.
The correlation of Adaptive Biotechnologies is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Adaptive Biotechnologies moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Adaptive Biotechnologies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Adaptive Biotechnologies can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adaptive Biotechnologies Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Adaptive Stock analysis
When running Adaptive Biotechnologies' price analysis, check to measure Adaptive Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptive Biotechnologies is operating at the current time. Most of Adaptive Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adaptive Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptive Biotechnologies' price. Additionally, you may evaluate how the addition of Adaptive Biotechnologies to your portfolios can decrease your overall portfolio volatility.
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Stocks Directory Find actively traded stocks across global markets | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |
Is Adaptive Biotechnologies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adaptive Biotechnologies. If investors know Adaptive will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adaptive Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.56) | Revenue Per Share 1.179 | Quarterly Revenue Growth (0.17) | Return On Assets (0.17) | Return On Equity (0.58) |
The market value of Adaptive Biotechnologies is measured differently than its book value, which is the value of Adaptive that is recorded on the company's balance sheet. Investors also form their own opinion of Adaptive Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Adaptive Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adaptive Biotechnologies' market value can be influenced by many factors that don't directly affect Adaptive Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adaptive Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adaptive Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adaptive Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.